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Abstract
Human epidermal growth factor receptor (HER)2 over-expression
is associated with a shortened disease-free interval and poor
survival. Although the addition of trastuzumab to chemotherapy in
the first-line setting has improved response rates, progression-free
survival, and overall survival, response rates declined when trastu-
zumab was used beyond the first-line setting because of multiple
mechanisms of resistance. Studies have demonstrated the clinical
utility of continuing trastuzumab beyond progression, and further
trials to explore this concept are ongoing. New tyrosine kinase
inhibitors, monoclonal antibodies, PTEN (phosphatase and tensin
homolog) pathway regulators, HER2 antibody-drug conjugates,
and inhibitors of heat shock protein-90 are being evaluated to
determine whether they may have a role to play in treating
trastuzumab-resistant metastatic breast cancer.
Introduction
As knowledge about the treatment of breast cancer has grown,
attention has increasingly focused on developing a targeted
approach to this diverse disease. In particular, treatment of
human epidermal growth factor receptor (HER)2/neu-positive
breast cancer has undergone significant advances since the
cloning of the HER2 oncogene in 1984 [1].
The HER2 oncogene encodes one of four transmembrane
receptors within the erbB family. Its over-expression, which
occurs in approximately 25% of all breast cancer tumors, is
associated with a shortened disease-free interval and poor
survival [2]. Following ligand binding, the glycoprotein
receptor is activated through homodimerization or hetero-
dimerization, leading to a cascade of events that involves
activation of the tyrosine kinase domain, Ras/Raf/mitogen-
activated protein kinase (MAPK) pathway, and phosphatidyl-
inositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR). This sequence promotes the rapid cell growth,
differentiation, survival, and migration that are associated with
HER2-positive breast cancers (Figure 1). Thus, women with
HER2-positive breast cancers exhibit significantly decreased
disease-free survival and overall survival (OS) [2-5].
This review discusses progress in the treatment of HER2-
positive metastatic breast cancer since the discovery of the
HER2 oncogene, with particular focus upon the mechanisms
of resistance to trastuzumab, treatment with trastuzumab
beyond progression, use of lapatinib, and new biologic
agents that may provide further therapeutic options in
patients with metastatic HER2-positive breast cancer.
Use of trastuzumab in the treatment of
metastatic breast cancer
Trastuzumab is a humanized recombinant monoclonal anti-
body, of the IgG1 type, which binds with high affinity to the
extracellular domain of the HER2 receptor. The mechanism
underlying trastuzumab’s efficacy in the treatment of HER2-
positive breast cancer is multifaceted and incompletely
understood. In vivo breast cancer models have demonstrated
that trastuzumab induces antibody-dependent cellular cyto-
toxicity through activation of Fc receptor expressing cells (for
example, macrophages and natural killer cells), leading to
lysis of tumor cells [6,7]. Trastuzumab has also been shown to
downregulate p185ErbB2 [8]. In addition, trastuzumab blocks
the release of the extracellular domain of HER2 by inhibiting
cleavage of the HER2 protein by ADAM (a disintegrin and
metalloproteinase domain) metalloproteinases [9]. Significant
declines in serum HER2 levels are a predictor of outcome
after trastuzumab-based therapy [10-12]. Furthermore, trastu-
zumab inhibits downstream PI3K-Akt signaling, leading to
apoptosis [13]. It has also been shown that trastuzumab
downregulates proteins that are involved in p27kip1 seques-
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tration, causing release of p27kip1 and enabling inhibition of
cyclin E/Cdk2 complexes and subsequent G1 arrest [14].
Moreover, trastuzumab has been shown to exert antiangio-
genic effects through normalization of microvessel density [15].
Although the mechanism that accounts for trastuzumab’s
antitumor activity remains incompletely understood and
requires further elucidation, the results of the inclusion of
trastuzumab in the treatment of HER2-positive breast cancer
are clear. Slamon and colleagues [16] found that addition of
trastuzumab to chemotherapy, in the first-line setting, resulted
in a significantly improved objective response, time to disease
progression, and OS. Combinations of trastuzumab with
taxanes, platinum salts, vinorelbine, and capecitabine have
yielded benefits in the treatment of HER2-positive metastatic
breast cancer [17-23]. However, other trials demonstrated
that response rates declined markedly when trastuzumab was
used beyond the first-line setting, indicating the development
of resistance to this agent.
Mechanisms of resistance to trastuzumab
PTEN/PI3K/mTOR/Akt pathways
PTEN (phosphatase and tensin homolog) is a tumor sup-
pressor gene that causes dephosphorylation of phosphotidyl-
inositol-3,4,5 triphosphate, which is the site that recruits the
pleckstrin-homology domain of Akt to the cell membrane
[24,25]. PTEN inhibits the ability of PI3K to catalyze the
production of phosphotidylinositol-3,4,5 triphosphate and
thus antagonizes the Akt cascade [26]. Loss of PTEN
function occurs in approximately 50% of all breast cancers
[27]. Restoration of PTEN expression impedes Akt activation
and increases apoptosis [28]. Nagata and coworkers [24]
demonstrated that inhibition of PTEN expression by antisense
oligonucleotides resulted in trastuzumab resistance in vitro
and in vivo. Specifically, tumors in which PTEN expression
was abrogated by antisense oligonucleotides exhibited tumor
growth patterns that were unaffected by trastuzumab
administration. Patients with PTEN-deficient tumors demon-
strated significantly lower complete response (CR) and
partial response (PR) rates to trastuzumab plus taxane
therapy than those who had PTEN-expressing tumors.
Independent of PTEN mutations, constitutive Akt phosphory-
lation may also occur in HER2-over-expressing tumors [29].
MUC4 overexpression
MUC4 is a membrane-associated, glycosylated mucin that
has been shown to be over-expressed in breast cancer cells
Figure 1
The HER2 family and interrelated signaling and events. The binding of ligands, including epidermal growth factor and transforming growth factor-α,
leads to the activation of signaling cascades involving Ras/Raf/MAPK, PI3K/Akt/mTOR, and JAK/STAT. This sequence of events promotes the
apoptosis, proliferation, survival, migration, angiogenesis, and metastasis of HER2-over-expressing breast cancers. BTC, betacellulin; EGF,
epidermal growth factor; EPG, epigen; EPR, epiregulin; HB-EGF, heparin-binding EGF-like growth factor; HER, human epidermal growth factor
receptor; JAK, Janus kinase; JNK, c-Jun N-terminal kinase 1; mTOR, mammalian target of rapamycin; MAPK, mitogen-activated protein kinase; MEK,
mitogen-induced extracellular kinase; MEKK, mitogen-activated protein/ERK kinase kinase; NRG, neuregulin; PI3K, phosphatidylinositol 3-kinase;
STAT, signal transducer and activator of transcription; TGF, transforming growth factor; TK, tyrosine kinase.[30]. In rat models, MUC4 forms a complex with the HER2
protein and potentiates its phosphorylation, leading to cell
proliferation [30,31]. In addition to its ligand activity, MUC4
inhibits binding of trastuzumab to the HER2 receptor.
Utilizing JIMT-1, a HER2-over-expressing cell line with primary
resistance to trastuzumab, Nagy and colleagues [32]
demonstrated that MUC4 expression was higher in this
trastuzumab-resistant cell line than in trastuzumab-sensitive
cell lines, and that the level of MUC4 expression inversely
correlated with the trastuzumab-binding capacity of single
tumor cells. Because the researchers found no mutations in
the coding sequence of HER2 in the JIMT-1 cell line, they
hypothesized that inhibition of trastuzumab binding was
mediated by MUC4-induced masking of the trastuzumab-
binding epitope [32].
Truncation of the HER2 receptor
Truncation of the HER2 receptor, as a result of proteolytic
shedding of the HER2 extracellular domain or via alternative
initiation from methionines located near to the trans-
membrane domain of the full-length molecule, can yield a
95-kDa fragment [33-35]. The p95HER2 fragment maintains
constitutive kinase activity and correlates with poor outcome
in patients with HER2-positive breast cancer [35]. This
truncated form of HER2 does not possess the extracellular
trastuzumab-binding epitope, and its expression has been
associated with trastuzumab resistance [36].
Activation of the insulin-like growth factor receptor-1
pathway
The insulin-like growth factor receptor-I (IGF-IR) is a trans-
membrane tyrosine kinase receptor whose activation is
associated with mitogenesis and cell survival [37]. Lu and
colleagues [38] showed that trastuzumab was rendered
ineffective by genetic alteration of the SKBR3 human breast
cancer cell lines to enable IGF-IR over-expression. Subse-
quently, addition of an IGF-binding protein that reduced
IGF-IR signaling restored trastuzumab’s ability to inhibit cell
growth. Utilizing the SKBR3 cell lines, Nahta and coworkers
[39] demonstrated that IGF-I stimulation led to increased
phosphorylation of HER2 in trastuzumab-resistant cells but
not in parental trastuzumab-sensitive cells. In addition,
inhibition of IGF-IR tyrosine activity reduced HER2 phos-
phorylation only in trastuzumab-resistant cells. Thus, there
exists substantial cross-talk between IGF-IR and HER2 in
trastuzumab-resistant cells.
Increased expression of vascular endothelial growth
factor
Du Manoir and colleagues [40] compared the levels of
vascular endothelial growth factor (VEGF) protein expression
in cell lines that had never been exposed to trastuzumab with
those cell lines that had acquired resistance to trastuzumab.
They found that VEGF protein expression was increased in
three out of four of the resistant cell lines; however, no signifi-
cant difference in VEGF mRNA expression was present,
implying that the increase in VEGF protein expression was
mediated by post-transcriptional changes. In addition, when
bevacizumab was added to a trastuzumab-based regimen for
mice bearing tumors of the 231-H2N cell line, a HER2-over-
expressing variant of the MDA-MB-231 cell line, tumor
growth was delayed significantly. Their cumulative findings
indicate that upregulation of VEGF may contribute to the
mechanism of trastuzumab resistance, and dual inhibition of
these pathways is currently being studied in phase I trials.
Treatment with trastuzumab beyond
progression
Disease progression after treatment with a trastuzumab-
based regimen in the first-line metastatic setting is met with
two options: continuation of trastuzumab alongside another
chemotherapeutic agent that is not cross-resistant, or
changing to a completely different (non-trastuzumab-based)
regimen. Evidence supporting the former approach first
appeared in an extension study, in which patients who had
progressed during the pivotal trial of trastuzumab plus
chemotherapy were offered further trastuzumab-based
treatment [41]. Concurrent chemotherapy was chosen at the
discretion of the treating physician. Researchers found that
the group of patients who had previously received
chemotherapy alone during the pivotal trial had a 14%
objective response rate and 32% clinical benefit rate (CR
plus PR plus stable disease for ≥6 months) during the
extension trial. Those who had already received a
trastuzumab-based regimen during the pivotal trial had a 11%
objective response rate and 22% clinical benefit rate. Median
duration of response was greater than 6 months in both
groups. These findings suggest that trastuzumab continues
to demonstrate clinical utility in the treatment of HER2-
positive metastatic breast cancer beyond progression. Four
retrospective studies have corroborated these results.
Stemmler and coworkers [42] found that patients who
received two or more trastuzumab-based regimens had a
significantly longer OS than did those who received only one
regimen (62.4 months versus 38.5 months; P = 0.01), indica-
ting that use of trastuzumab beyond progression is a valid
option in this group of patients. In addition, the Hermine
retrospective cohort study [43] demonstrated that, when
compared with patients who discontinued trastuzumab upon
progression of disease, those who continued to receive a
trastuzumab-based regimen beyond progression exhibited an
improvement both in time to progression (TTP) and in median
OS. Another study, conducted by Gelmon and colleagues
[44], revealed that overall response rate to trastuzumab alone
or with a taxane as the first regimen was 39%; a further 30%
of patients had stable disease as the best response. These
rates declined only slightly (36% and 38% for overall
response rate and stable disease, respectively) after a
second regimen of trastuzumab (alone or in combination with
paclitaxel or vinorelbine) was administered. Patients who
received further trastuzumab-based regimens beyond disease
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when compared with those who received only one
trastuzumab-based regimen (38.5 months versus 62.4 months;
P = 0.01).
A fourth study - a retrospective analysis of 101 patients who
continued to receive a trastuzumab-containing regimen
beyond progression - was reported this year [45]. It demon-
strated a trend toward improvement in response rates (35%
versus 16%) and median OS rates (70 months versus
56 months) in the patients who continued on trastuzumab,
but the findings were not statistically significant.
Although the results of these retrospective studies are
encouraging, these analyses suffer from the inherent limita-
tions of retrospective chart review, lack of uniformity in
chemotherapy choice, and evaluation of adverse events in
only the retrospective setting [46].
Recently, interim results from three prospective trials were
reported that support the use of trastuzumab beyond disease
progression on a trastuzumab-based regimen [47]. Bachlot
and colleagues [48] presented the results of a phase II trial
that evaluated the response rate to second-line treatment
with the combination of trastuzumab and vinorelbine, after
progression of disease on a first-line regimen of trastuzumab
plus taxane. They found that the overall response rate in this
second-line setting was 29%, with two patients showing a
CR. Furthermore, von Minckwitz and coworkers [49]
presented the results of the TBP (Treatment Beyond
Progression) trial, in which women who had progressed while
on a trastuzumab-based regimen were randomly assigned to
treatment with capecitabine monotherapy or capecitabine
plus trastuzumab. The women who received both capecita-
bine and trastuzumab demonstrated an improvement in TTP
(33 weeks versus 24 weeks), although this finding was not
statistically significant (P = 0.178). O’Shaughnessy and
colleagues [50] conducted a randomized phase III trial of
lapatinib versus lapatinib plus trastuzumab in heavily pre-
treated patients who had progressed after trastuzumab-
based therapy. In this study, the TTP was improved in
patients treated with trastuzumab plus lapatinib (P = 0.029).
Given the importance of this issue, two other randomized
phase III trials are poised to address the use of trastuzumab
beyond progression: THOR (Trastuzumab Halted or Retained)
and Pandora. The THOR and Pandora trials are phase III trials
that will randomly assign patients, who progressed on a first-
line regimen of trastuzumab plus chemotherapy, to continue or
discontinue trastuzumab while receiving a second-line
chemotherapy of the investigator’s choice.
New agents in the treatment of HER2-
positive breast cancer
Since the identification of the HER2 oncogene, development
of new agents targeting the HER2 pathway has led to
significant improvement in the treatment of HER2-positive
metastatic breast cancer (Table 1).
Tyrosine kinase inhibitors
Lapatinib
Lapatinib is an orally bioavailable, small-molecule dual
inhibitor of the tyrosine kinase activity of epidermal growth
factor receptor (EGFR) and HER2. It reversibly binds to the
cytoplasmic ATP-binding site of the intracellular tyrosine
kinase, preventing receptor phosphorylation and downstream
signaling of several pathways, including Akt and MAPK [51].
Its targeting of the kinase domain of HER2 enables this agent
to retain activity in trastuzumab-resistant tumor cells that over-
express the truncated HER2 receptor (p95HER2). Treatment
of p95HER2-expressing cells with lapatinib has been shown
to reduce p95HER2 phosphorylation, impede downstream
activation of Akt and MAPK, and inhibit cell proliferation [36].
In addition, an analysis of the tumor samples of 46 patients
with metastatic breast cancer who were treated with
trastuzumab demonstrated that only one out of nine patients
who expressed p95HER2 responded to trastuzumab,
whereas 19 of the 37 patients with tumors expressing full-
length HER2 achieved either a CR or a PR (P = 0.029) [36].
These findings indicate that there may be a role for lapatinib,
or another tyrosine kinase inhibitor, in the treatment of
p95HER2-related trastuzumab resistance.
The preclinical studies of lapatinib eventually led to a pivotal
phase III trial that involved patients with HER2-positive
advanced or metastatic breast cancer who had progressed
after treatment with a regimen that included an anthracycline,
a taxane, and trastuzumab [52]. The study randomly assigned
these patients to receive treatment with capecitabine mono-
therapy versus lapatinib plus capecitabine, and an interim
analysis demonstrated that the combination of lapatinib plus
capecitabine yielded a significant improvement in TTP
(hazard ratio [HR] = 0.49; one-sided P = 0.00016). However,
it should be noted that OS was equivalent in the treatment
arms. Researchers noted a trend toward improvement in the
occurrence of cerebral nervous system metastases in the
combination group. Updated results of this trial confirmed the
improved TTP due to the combination of lapatinib plus
capecitabine (27 weeks versus 19 weeks), with a HR of 0.57
(P = 0.00013) [53]. Furthermore, the updated findings
demonstrated a trend toward an improvement in OS,
although this result was not statistically significant (HR =
0.78, P = 0.177). The results of this trial led to the US Food
and Drug Administration’s approval of lapatinib, in combi-
nation with capecitabine, in the treatment of patients with
advanced or metastatic HER2-positive breast cancer that
progressed after trastuzumab, anthracyclines, and taxanes.
A recent phase III trial randomly assigned patients with
metastatic breast cancer, which was negative or untested for
HER2, to receive first-line treatment with paclitaxel mono-
therapy versus paclitaxel and lapatinib [54]. Overall, the study
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OS with the addition of lapatinib to paclitaxel therapy.
However, in a planned subgroup analysis, the authors found
that - among patients who were HER2 positive - the addition
of lapatinib to paclitaxel resulted in significant improvements
in TTP (HR = 0.53; P = 0.005) and event-free survival (HR =
0.52; P = 0.004). In these HER2-positive patients, OS was
also increased in the paclitaxel-lapatinib arm, but this
difference was not statistically significant (P = 0.365). These
findings support further studies exploring the use of lapatinib-
based regimens in the first-line treatment of HER2-positive
metastatic breast cancer.
Based upon preclinical data indicating that the combination
of trastuzumab and lapatinib may produce synergistic
inhibition of cell proliferation, a phase I study involving this
combination was conducted in patients with advanced or
metastatic HER2-positive breast cancer [55,56]. The most
frequent drug-related grade 3 events were diarrhea (17%),
fatigue (11%), and rash (6%). The combination regimen
resulted in one CR and seven PRs. All eight responders had
received prior trastuzumab therapy in combination with
cytotoxic chemotherapy. Furthermore, six patients had stable
disease for longer than 6 months. Because of these encoura-
ging results, a double-blind, placebo-controlled, phase III
study was initiated to determine whether the addition of
lapatinib to a combination of trastuzumab and paclitaxel will
render an improvement in TTP [57]. This trial will also
evaluate the incidence of central nervous system metastases
among these groups, given the encouraging findings in the
previous pivotal trial, in order to investigate further the
hypothesis that the small molecule tyrosine kinase inhibitors,
unlike the monoclonal antibodies, may be able to cross the
blood-brain barrier effectively.
HKI-272
HKI-272 is a potent and irreversible inhibitor of the tyrosine
kinase domains of EGFR and HER2, resulting in arrest at the
G1-S (Gap 1/DNA synthesis) phase [58]. Preliminary results
of an open-label, phase II study involving HKI-272 in the
treatment of women with advanced or metastatic HER2-
positive breast cancer [59] revealed six confirmed PRs, as
well as additional patients with unconfirmed PRs. Diarrhea
was the only grade 3 to 4 treatment-related adverse event
that occurred in more than one patient. This trial continues to
accrue patients.
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Table 1
Therapeutic agents targeting the HER2 pathway in breast cancer
Agent Molecule Target/mechanism Status
Trastuzumab Monoclonal antibody Blocks extracellular domain of HER2 US FDA approved in metastatic and 
adjuvant settings [16]
Pertuzumab (2C4) Monoclonal antibody Blocks HER2 and HER3 dimerization Phase III (with trastuzumab) 
Trastuzumab-DM1 Antibody-drug conjugate Binds HER2, conjugate is internalized,  Phase III
and DM1 toxin causes cancer cell death 
Ertumaxomab Monoclonal antibody Trifunctional anti-HER2 x anti-CD3 antibody  Phase II
Lapatinib Small molecule TKI Reversible inhibitor of EGFR and HER2 TK FDA approved in metastatic setting 
[52]
Gefitinib Small molecule TKI Reversible inhibitor of EGFR Phase II (discontinued because of 
poor results)
Erlotinib Small molecule TKI Reversible inhibitor of EGFR Phase II
HKI-272 Small molecule TKI Irreversible inhibitor of the HER-2 and  Phase I/II
EGFR TK
BIBW2992 Small molecule TKI Irreversible inhibitor of the HER-2 and  Phase II
EGFR TK
Temsirolimus (CCI779) Rapamycin analogue mTOR inhibitor and Akt deactivation Phase III (with letrozole)
Everolimus (RAD001) Rapamycin analogue mTOR inhibitor and Akt deactivation Phase III (with paclitaxel)
Tanespimycin (17AAG) Derivate of geldanamycin Hsp-90 inhibitor (anti-downstream  Phase II
pathway element)
Tipifarnib Analogue of imidazole farnesyltranstransferase inhibitor  Phase II (with chemo and/or 
(downstream pathway element) homonaltherapy)
GDC-0941 Small molecule PI3K inhibitor Phase I 
EGFR, epidermal growth factor receptor; FDA, Food and Drug Administration; HER, human epidermal growth factor receptor; Hsp, heat shock
protein; mTOR, mammalian target of rapamycin; TK, tyrosine kinase; TKI, tyrosine kinase inhibitor.Gefitinib and erlotinib
Gefitinib and erlotinib are small-molecule EGFR tyrosine
kinase inhibitors. Previous preclinical studies have been
contradictory. For example, in one study [60] the combination
of gefitinib and trastuzumab resulted in a synergistic inhibition
of the SK-Br-3 and BT-474 breast carcinoma cell lines, both
of which express EGFR and ErbB-2. However, these findings
were not confirmed in breast cancer xenograft models, which
demonstrated that gefitinib did not further reduce tumor cell
viability in trastuzumab-treated tumors [61]. In phase II clinical
trials of single-agent gefitinib and single-agent erlotinib, the
response rates were less than 5% [62]. A phase I/II trial was
conducted in which patients with HER2-positive metastatic
breast cancer who had previously received between 0 to 2
chemotherapy regimens were treated with a combination of
trastuzumab (2 mg/kg per week) and gefitinib (250 to
500 mg/day). Within the chemotherapy-naïve group, one CR,
one PR, and seven instances of stable disease were
reported. However, no responses were seen among patients
who had previously been treated. Thus, at the time of the
interim analysis, the TTP did not meet predetermined
statistical end-points required for study continuation, and the
study was halted [63]. Moreover, the abbreviated TTP (2.5 to
2.9 months) observed in this trial suggests a possible
antagonistic interaction between gefitinib and trastuzumab.
Pazopanib
Pazopanib is a tyrosine kinase inhibitor of VEGF receptor-1,
-2 and -3, platelet-derived growth factor-α and -β, and c-kit. A
phase I study evaluating the use of pazopanib in various solid
tumors demonstrated that the agent was well tolerated [64].
Preliminary efficacy results revealed a minimal response in
four patients; six other patients exhibited stable disease for
longer than 6 months. Based upon encouraging preclinical
data supporting the combination of lapatinib and pazopanib,
a phase I open-label trial involving 33 patients with solid
tumors was initiated [65]. It demonstrated that 10 patients
experienced stable disease for longer than 16 weeks, and
three patients had PRs. Thus, a phase II, open-label
randomized trial began in 2006 and is ongoing. This study
randomly assigned patients to receive treatment with
lapatinib plus pazopanib, versus lapatinib alone, in the first-
line treatment of advanced or metastatic HER2-positive
breast cancer [66,67]. Preliminary efficacy results revealed
that the progressive disease rate was 69% in the combina-
tion group versus 27% in the lapatinib monotherapy group.
Monoclonal antibodies
Pertuzumab
Pertuzumab is an IgG1 monoclonal antibody that binds to
HER2 at the dimerization domain, sterically preventing
heterodimerization [68,69]. The pertuzumab-binding site
does not overlap with the trastuzumab epitope on HER2
[70,71]. Preclinical studies demonstrated that trastuzumab
and pertuzumab synergistically inhibited the survival of
BT474 cells, reduced levels of total and phosphorylated
HER2 protein, and blocked receptor signaling through Akt
[72]. A phase I dose escalation study of pertuzumab in 21
patients with advanced cancers showed that pertuzumab
was well tolerated and led to a partial response in two
patients and stable disease in six patients [73]. Thus, a
single-arm, two-stage phase II trial, involving patients with
HER2-positive metastatic breast cancer who had received up
to three lines of prior therapy and had developed disease
progression during trastuzumab-based therapy, is in
progress. Interim results revealed that, among the 33
evaluable patients, one CR and five PRs had occurred
[74,75]. In addition, seven patients exhibited stable disease
for longer than 6 months, and 10 patients had stable disease
for less than 6 months. Recruitment into the second stage of
this study is ongoing.
Bevacizumab
Bevacizumab is a monoclonal antibody to VEGF, which was
approved this year by the US Food and Drug Administration
to be used in combination with paclitaxel for the treatment of
metastatic HER2-negative breast cancer. Encouraging pre-
clinical studies demonstrated the benefit of adding
bevacizumab to trastuzumab, as compared with treatment
with trastuzumab alone, in order to inhibit tumor growth
further in a breast cancer xenograft model [40]. A phase I,
open-label, dose-escalation trial assessed the optimal dose
schedule and safety of bevacizumab in combination with
trastuzumab [76]. The study showed that co-administration of
these agents did not alter the pharmacokinetics of either
drug, and no grade 3 or 4 adverse events occurred. Prelimi-
nary efficacy results showed one CR, four PRs, and two
patients with stable disease among nine evaluable patients.
Based upon these encouraging results, a phase II extension
study was initiated to evaluate the efficacy of this combination
in the first-line treatment of patients with HER2-positive
metastatic breast cancer. Of the 37 patients who were
evaluated in this trial, preliminary findings demonstrated one
CR and 19 PRs; the combination of bevacizumab and
trastuzumab without chemotherapy produced an overall
response rate of 54%. Furthermore, a phase III study has
been initiated that will randomly assign patients to receive
either bevacizumab and trastuzumab and docetaxel, versus
trastuzumab plus docetaxel [77]. The primary end-point of
this study will be progression-free survival; secondary out-
come measures will include OS, best overall response,
duration of response, time to treatment failure, quality of life,
and cardiac safety.
Regulators of the PTEN/P13K/mTOR/Akt pathways
Everolimus is a macrolide that selectively inhibits mTOR.
Because PTEN deficiency, which occurs in approximately
50% of all breast cancers, leads to constitutive activation of
Akt and subsequent activation of mTOR, inhibitors of mTOR
add potential additive benefit to biologic or chemotherapy.
Preclinical testing demonstrated that, after the breast cancer
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trastuzumab resistant through transfection with PTEN anti-
sense oligonucleotides, the combination of RAD001 and the
Akt inhibitor triciribine restored trastuzumab sensitivity and
markedly increased growth inhibition by trastuzumab [78]. A
phase I/II trial, involving the use of RAD001 in combination
with trastuzumab for the treatment of patients with HER2-
positive metastatic breast cancer that has progressed on
trastuzumab-based therapy, is ongoing at our institution.
HER2 antibody-drug conjugates
Trastuzumab-DM1 is a novel HER2 antibody-drug conjugate
in which trastuzumab is chemically linked to a highly potent
maytansine-derived antimicrotubule drug (DM1). Xenograft
models have established the efficacy of this compound in
both trastuzumab-sensitive and trastuzumab-resistant breast
tumors [79]. Recently, the results of a phase II trial involving
trastuzumab-DM1 in the treatment of metastatic breast
cancer that had progressed on HER2-directed therapy
(trastuzumab, lapatinib, or both) were presented [80].
Twenty-five percent of patients demonstrated a confirmed
objective response, and 35% of patient demonstrated clinical
benefit, which consisted of either a confirmed objective
response or stable disease lasting for at least 6 months.
Inhibitors of heat shock protein-90
The heat shock protein-90 is a chaperone protein that
enables the proper folding of newly synthesized client
proteins, such as HER2, into a stable tertiary conformation.
Geldanamycin, an ansamycin antibiotic, was first isolated
from  Streptomyces hygroscopicus and noted to have
inhibitory activity against heat shock protein-90 [81,82].
However, because of geldamycin’s narrow therapeutic
widow, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG)
was derived from the initial compound [82]. Preclinical
studies involving 17-AAG revealed that it reduced cellular
proliferation of the trastuzumab-resistant cell line JIMT-1 [83].
The antiproliferative effect of 17-AAG was positively
correlated with phosphorylation and downregulation of
HER2, and was dominated by apoptosis. Thus, a phase I
dose-escalation study was initiated, in which patients with
advanced solid tumors who had progressed during standard
therapy were treated with weekly trastuzumab followed by
intravenous tanespimycin (17-AAG). Among the 25 patients
enrolled, one PR, four minor responses, and four patients with
stable disease were noted [84]. The authors observed that
tumor regressions were seen only in patients with HER2-
positive metastatic breast cancer.
Economic implications of targeted therapy
Unfortunately, most countries experience economic pressures
on health care, resulting in the need to evaluate the cost-
effectiveness of utilizing targeted therapy for the treatment of
HER2-positive metastatic breast cancer. Specifically,
trastuzumab is being closely studied in this setting. Norum
and colleagues [85] conducted a cost-effectiveness study in
which they reviewed cost per life year in clinical trials
involving chemotherapy with or without trastuzumab. They
found that the cost per life year saved with the use of
trastuzumab ranged between €63,137 and €162,417,
depending on survival gain and discount rate employed.
However, this study has been criticized for its failure to
account for the ability of trastuzumab to reduce the incidence,
and thus the cost of treatment, of relapses [86]. A French
open-control study evaluated the cost-effectiveness ratio of
trastuzumab in combination with paclitaxel when compared
with conventional chemotherapy [87]. This study found that
the additional cost per saved year of life of trastuzumab,
expressed as the incremental cost-effectiveness ratio, was
€15,370. Although this figure may be acceptable in a
developed country that has adequate resources, the Breast
Health Global Initiative Therapy Focus Group has noted that
the price of monoclonal antibodies may exceed the resources
of low-resource countries [88].
Conclusions
In the years that have intervened since the discovery of the
HER2 oncogene, the use of trastuzumab has revolutionized
the treatment of HER2-positive breast cancer. However, as
the success of trastuzumab has grown, its limitations have
become apparent in a parallel manner. Although mechanisms
of trastuzumab resistance have been described, a complete
understanding of these pathways requires elucidation of the
interactions within and between their members. Multifaceted
novel strategies that target these alternative pathways are
necessary to overcome the adaptive mechanisms of this
genetically diverse population and thus increase the
likelihood of establishing lasting antitumor efficacy.
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